Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776216 | 1.00 | KMT2A (0.54) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL29428717 | 0.84 | KMT2A (0.65) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1325225 | 0.84 | KMT2A (0.65) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL6039621 | 0.81 | KMT2A (0.75) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL30168472 | 0.81 | KMT2A (0.75) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL29439591 | 0.80 | KMT2A (0.47) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL628538 | 0.80 | KMT2A (0.47) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL16659002 | 0.77 | NPC1 (0.34) | KMT2ANPC1NTRK1 | |
| SCHEMBL2160733 | 0.76 | MEN1 (0.54) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL10976128 | 0.76 | MEN1 (0.44) | KMT2AMEN1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914277-B | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| CN-110914277-A | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-2934518-B1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2020-02-19 | — | — | EP | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2844252-B1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160229825-A1 | SYNTHETIC PROCESS FOR PREPARING 2-FUROIC ACID DERIVATIVES | DERMIRA, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9353101-B2 | Cyclic amine substituted heterocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2934518-A1 | SPIROCYCLIC CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2014099836-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099836-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-0316491-A1 | Herbicidal 2-pyridyl and 2-pyrimidine carbonyl 1,3-cyclohexanediones | STAUFFER AGRICULTURAL CHEMICALS COMPANY, INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| US-4708732-A | 2-(pyrimidinecarbonyl)-1,3-cyclohexanediones and their use as herbicidal agents | STAUFFER CHEMICAL COMPANY (US) | 1987-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | CETP, APOB, MTTP | KMT2A 1708/4885MEN1 2325/4885MAPT 2846/4885 |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | WEE1, WEE2, CCNE1 | KMT2A 1427/4885MEN1 2280/4885MAPT 4290/4885 |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | CETP, MTTP, LCAT | KMT2A 4339/4885MEN1 3568/4885MAPT 2950/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | KMT2A 1427/4885MEN1 2280/4885MAPT 4290/4885 |
| US-20160229825-A1 | SYNTHETIC PROCESS FOR PREPARING 2-FUROIC ACID DERIVATIVES | ALAD, CYP4F2, CYP2F1 | KMT2A 1455/4885MEN1 2178/4885MAPT 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.